UTHR insider trading
NasdaqGS HealthcareUNITED THERAPEUTICS Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About UNITED THERAPEUTICS Corp
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Company website: www.unither.com
UTHR insider activity at a glance
FilingIQ has scored 8,549 insider transactions for UTHR since Aug 15, 2014. The most recent filing in our index is dated Aug 20, 2026.
Across the full history, 6 open-market purchases
and 5,596 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on UTHR insider trades is 67.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest UTHR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading UTHR
13F funds holding UTHR
Frequently asked
- How many insider trades does FilingIQ track for UTHR?
- FilingIQ tracks 8,549 Form 4 insider transactions for UTHR (UNITED THERAPEUTICS Corp), covering filings from Aug 15, 2014 onwards. 983 of those were filed in the last 90 days.
- Are UTHR insiders net buyers or net sellers?
- Across the full Form 4 history for UTHR, 6 transactions (0%) were open-market purchases and 5,596 (65%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does UTHR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is UTHR in?
- UNITED THERAPEUTICS Corp (UTHR) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $21.46B.
Methodology & sources
Every UTHR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.